rs397517141
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PP3_Strong
The ENST00000311189.8(HRAS):c.401C>T(p.Ala134Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A134T) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000311189.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HRAS | NM_005343.4 | c.401C>T | p.Ala134Val | missense_variant | 4/6 | ENST00000311189.8 | NP_005334.1 | |
HRAS | NM_176795.5 | c.401C>T | p.Ala134Val | missense_variant | 4/6 | ENST00000417302.7 | NP_789765.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HRAS | ENST00000311189.8 | c.401C>T | p.Ala134Val | missense_variant | 4/6 | 1 | NM_005343.4 | ENSP00000309845 | P1 | |
HRAS | ENST00000417302.7 | c.401C>T | p.Ala134Val | missense_variant | 4/6 | 5 | NM_176795.5 | ENSP00000388246 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 11, 2013 | The Ala134Val variant in HRAS has not been reported in the literature or in larg e population studies, but has been identified in one affected son and his unaffe cted mother by our laboratory. A different variant causing a change at this sam e residue, Ala134Ser, has been reported in one individual with acute lymphoblast ic leukemia (ALL, COSMIC database), which may suggest that a change at this amin o acid position is not tolerated. Computational analyses (biochemical amino acid properties, conservation, AlignGVGD, PolyPhen2, and SIFT) suggest that the Ala1 34Val variant may impact the protein. However, this information is not enough to assume pathogenicity. In summary, additional information is needed to fully ass ess the clinical significance of the Ala134Val variant. - |
Costello syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 134 of the HRAS protein (p.Ala134Val). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with HRAS-related conditions. ClinVar contains an entry for this variant (Variation ID: 45303). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HRAS protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at